Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys Licenses Molecular Modeling Tech to Axxima

NEW YORK, June 19 - Accelrys has licensed its molecular-modeling technology, including the LigandFit software, to Axxima Pharmaceuticals for three years, the companies said today.


Axxima will use the molecular-modeling technology to target infectious diseases, including HIV, hepatitis C, and tuberculosis.

According to Accelrys, a wholly owned subsidiary of drug maker Pharmacopeia, LigandFit calculates the likelihood that a compound might react to protein targets.

Financial details were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.